AVROBIO, One Kendall Square, Building 300, Suite 201, Cambridge, MA 02139, USA.
Regen Med. 2021 Oct;16(10):905-908. doi: 10.2217/rme-2021-0126. Epub 2021 Oct 8.
Geoff MacKay is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is currently the president and CEO of AVROBIO, a clinical-stage lentiviral gene therapy company that treats lysosomal disorders, and a board member of Talaris Therapeutics and Satellos Bioscience. He is also the founding CEO of eGenesis, a biotech that applies CRISPR-Cas9 gene editing to xenotransplantation and the former president and CEO of Organogenesis, a world-leading cell therapy company. Earlier in his career, MacKay spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise.
杰夫·麦凯（Geoff MacKay）是细胞和基因治疗领域的先驱，在创新型生物技术公司拥有成功领导的记录。他现任 AVROBIO 的总裁兼首席执行官，AVROBIO 是一家临床阶段慢病毒基因治疗公司，专注于治疗溶酶体贮积症，同时他还担任 Talaris Therapeutics 和 Satellos Bioscience 的董事会成员。他还是 eGenesis 的创始首席执行官，eGenesis 是一家将 CRISPR-Cas9 基因编辑应用于异种移植的生物技术公司，也曾担任 Organogenesis 的总裁兼首席执行官，Organogenesis 是一家全球领先的细胞治疗公司。在职业生涯早期，麦凯曾在诺华公司工作 11 年，担任全球移植和免疫学业务的高级领导职务。
